| 1 | Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity | 0.6 | 6 | Citations (PDF) |
| 2 | NK Cell and Monocyte Dysfunction in Multisystem Inflammatory Syndrome in Children | 0.6 | 3 | Citations (PDF) |
| 3 | Immunotherapeutic strategies for treating opioid use disorder and overdose | 4.0 | 11 | Citations (PDF) |
| 4 | IL-4 Predicts the Efficacy of a Candidate Antioxycodone Vaccine and Alters Vaccine-Specific Antibody-Secreting Cell Proliferation in Mice | 0.6 | 6 | Citations (PDF) |
| 5 | Efficacy and Selectivity of Monovalent and Bivalent Vaccination Strategies to Protect against Exposure to Carfentanil, Fentanyl, and Their Mixtures in Rats | 3.7 | 21 | Citations (PDF) |
| 6 | Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder | 3.2 | 18 | Citations (PDF) |
| 7 | Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in Rats | 4.3 | 22 | Citations (PDF) |
| 8 | Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development | 3.2 | 26 | Citations (PDF) |
| 9 | Countermeasures for Preventing and Treating Opioid Overdose | 4.9 | 62 | Citations (PDF) |
| 10 | A covalent poly(lactic acid) naloxone nanoparticle reduces fentanyl‐induced poisoning in rats | 0.7 | 1 | Citations (PDF) |
| 11 | IND‐enabling studies of vaccines to treat heroin and oxycodone use disorders | 0.7 | 0 | Citations (PDF) |
| 12 | Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge | 5.4 | 39 | Citations (PDF) |
| 13 | Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders | 0.6 | 12 | Citations (PDF) |
| 14 | Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats | 3.2 | 4 | Citations (PDF) |
| 15 | Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning | 3.7 | 18 | Citations (PDF) |
| 16 | Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder | 4.4 | 25 | Citations (PDF) |
| 17 | A Membrane-Modulated Centrifugal Microdevice for Enzyme-Linked Immunosorbent Assay-Based Detection of Illicit and Misused Drugs | 6.5 | 9 | Citations (PDF) |
| 18 | Sex differences in oral oxycodone self‐administration and stress‐primed reinstatement in rats | 2.7 | 56 | Citations (PDF) |
| 19 | Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats | 3.3 | 46 | Citations (PDF) |
| 20 | Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity | 5.6 | 45 | Citations (PDF) |
| 21 | Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders | 5.4 | 20 | Citations (PDF) |
| 22 | Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity | 3.3 | 18 | Citations (PDF) |
| 23 | Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system | 5.5 | 72 | Citations (PDF) |
| 24 | Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity | 3.2 | 8 | Citations (PDF) |
| 25 | Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone | 4.8 | 25 | Citations (PDF) |
| 26 | Development of vaccines to treat opioid use disorders and reduce incidence of overdose | 4.4 | 82 | Citations (PDF) |
| 27 | Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation | 4.3 | 18 | Citations (PDF) |
| 28 | A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats | 3.3 | 85 | Citations (PDF) |
| 29 | Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders | 3.2 | 22 | Citations (PDF) |
| 30 | Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose | 3.5 | 35 | Citations (PDF) |
| 31 | Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats | 3.3 | 51 | Citations (PDF) |
| 32 | Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins | 4.3 | 56 | Citations (PDF) |
| 33 | Oxycodone self-administration in male and female rats | 2.9 | 111 | Citations (PDF) |
| 34 | Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse | 2.4 | 62 | Citations (PDF) |
| 35 | Biologics to treat substance use disorders: Current status and new directions | 3.2 | 47 | Citations (PDF) |
| 36 | GIRK Channels Modulate Opioid-Induced Motor Activity in a Cell Type- and Subunit-Dependent Manner | 3.7 | 59 | Citations (PDF) |
| 37 | The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence | 3.2 | 16 | Citations (PDF) |
| 38 | The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse | 0.6 | 43 | Citations (PDF) |
| 39 | Effect of Currently Approved Carriers and Adjuvants on the Pre-Clinical Efficacy of a Conjugate Vaccine against Oxycodone in Mice and Rats | 2.4 | 52 | Citations (PDF) |
| 40 | Effects of an Oxycodone Conjugate Vaccine on Oxycodone Self-Administration and Oxycodone-Induced Brain Gene Expression in Rats | 2.4 | 67 | Citations (PDF) |
| 41 | Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse | 1.5 | 31 | Citations (PDF) |
| 42 | Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum | 3.2 | 41 | Citations (PDF) |
| 43 | Selective Effects of a Morphine Conjugate Vaccine on Heroin and Metabolite Distribution and Heroin-Induced Behaviors in Rats | 3.3 | 68 | Citations (PDF) |
| 44 | Reduced Antinociception of Opioids in Rats and Mice by Vaccination with Immunogens Containing Oxycodone and Hydrocodone Haptens | 5.6 | 69 | Citations (PDF) |
| 45 | Immunogenicity of Individual Vaccine Components in a Bivalent Nicotine Vaccine Differ According to Vaccine Formulation and Administration Conditions | 2.4 | 27 | Citations (PDF) |
| 46 | High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants | 3.2 | 57 | Citations (PDF) |
| 47 | An Oxycodone Conjugate Vaccine Elicits Drug-Specific Antibodies that Reduce Oxycodone Distribution to Brain and Hot-Plate Analgesia | 3.3 | 88 | Citations (PDF) |
| 48 | Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats | 3.2 | 83 | Citations (PDF) |
| 49 | Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities | 5.2 | 60 | Citations (PDF) |
| 50 | Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist | 2.4 | 14 | Citations (PDF) |
| 51 | Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats | 5.2 | 31 | Citations (PDF) |
| 52 | Altered neurotransmission in the mesolimbic reward system of <i>Girk</i><sup>−<i>/</i>−</sup> mice | 3.9 | 47 | Citations (PDF) |
| 53 | R7BP Complexes With RGS9-2 and RGS7 in the Striatum Differentially Control Motor Learning and Locomotor Responses to Cocaine | 5.5 | 47 | Citations (PDF) |
| 54 | Absence and Rescue of Morphine Withdrawal in GIRK/Kir3 Knock-out Mice | 3.7 | 69 | Citations (PDF) |
| 55 | Predisposition to late-onset obesity in GIRK4 knockout mice | 7.6 | 46 | Citations (PDF) |
| 56 | Expression and Localization of RGS9-2/G 5/R7BP Complex In Vivo Is Set by Dynamic Control of Its Constitutive Degradation by Cellular Cysteine Proteases | 3.7 | 60 | Citations (PDF) |
| 57 | Inhibition of Nitric Oxide Synthase Enhances Cocaine's Developmental Toxicity: Vascular and CNS Effects | 5.5 | 3 | Citations (PDF) |
| 58 | Vasoconstriction Caused by Cocaine is Enhanced by Sodium Salicylate: Is Inducible Nitric Oxide Synthase mRNA Related? | 5.5 | 3 | Citations (PDF) |
| 59 | Quantification of Housekeeping Transcript Levels During the Development of Bovine Preimplantation Embryos1 | 2.6 | 183 | Citations (PDF) |
